Free Communications - Vaccines 3

3:30 PM • FC 11-01 • One dose of human papillomavirus vaccine is as effective as three for prevention of high-grade cervical lesions: national cohort study > J. Julia BROTHERTON 3:41 PM • FC 11-02 • Reduction in HPV16/18 positive high-grade cervical lesions in a population offered catch-up vaccination > S. Suzanne Garland 3:52 PM • FC 11-03 • Comparable vaccine effectiveness against cervical intraepithelial neoplasia after vaccination with two or three doses of the quadrivalent human papillomavirus vaccine > R. Robine Donken 4:03 PM • FC 11-04 • Protective efficacy of the AS04-human papillomavirus (HPV)-16/18 vaccine against non-vaccine HPV types among young women with current HPV exposure: post-HOC analysis from a randomized controlled trial > F-H. Fang-Hui ZHAO 4:14 PM • FC 11-05 • Bivalent HPV vaccine effectiveness in a Japanese population > R. RISA Kudo 4:25 PM • FC 11-06 • Long-term antibody response to human papillomavirus vaccines: up to 12 years follow-up in the Finnish maternity cohort > H. Helena Faust 4:36 PM • FC 11-07 • Impact of HPV vaccination with GARDASIL® in Switzerland > M. Martine Jacot-Guillarmod 4:47 PM • FC 11-08 • HPV vaccine for women undergoing excisional treatment for HSIL/CIN2-3: role in the reduction of the risk of persistent/recurrent intraepitelial lesions > M. Marta Del Pino